NCT02302157View on ClinicalTrials.gov

Dose Escalation Study of AST-OPC1 in Spinal Cord Injury

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

December 31, 2018

Conditions
Cervical Spinal Cord InjurySpine InjurySpinal Cord Trauma
Interventions
BIOLOGICAL

AST-OPC1

One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent

Trial Locations (9)

19107

Thomas Jefferson University/Magee Rehabilitation, Philadelphia

30309

Shepherd Center, Atlanta

46202

Indiana University, Indianapolis

53226

Medical College of Wisconsin, Milwaukee

60612

Rush University Medical Center, Chicago

63110

Washington University, St Louis

92093

Univ. of California at San Diego, La Jolla

95128

Stanford University/Santa Clara Valley Medical Center, San Jose

Unknown

Rancho Los Amigos/USC, Los Angeles

Sponsors
All Listed Sponsors
lead

Lineage Cell Therapeutics, Inc.

INDUSTRY

NCT02302157 - Dose Escalation Study of AST-OPC1 in Spinal Cord Injury | Biotech Hunter | Biotech Hunter